ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Clinical trials for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) explained in plain language.
Never miss a new study
Get alerted when new ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) trials appear
Sign up with your email to follow new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising pneumonia therapy trial pulled before it began
Disease control TerminatedThis study was designed to test whether adding an experimental drug and special immune cells to standard care could help critically ill adults with severe pneumonia, especially those with sepsis or lung failure. The trial was withdrawn before enrolling any participants, so no res…
Matched conditions: ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New antibody aimed at ARDS shows promise in early trial
Disease control OngoingThis study tests a single dose of an antibody called ALT-100 in people with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The trial involves 15 hospitalized adults and compares the drug to a placebo. The main goal is to check sa…
Matched conditions: ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Phase: PHASE2 • Sponsor: Aqualung Therapeutics Corp. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
AI vs. doctors: can a computer make the right call for sepsis?
Knowledge-focused ENROLLING_BY_INVITATIONThis study asks 350 critical care doctors and advanced practice providers to review fictional patient cases of sepsis and ARDS. Each case includes treatment recommendations that were either made by a real clinician or generated by an artificial intelligence system. The participan…
Matched conditions: ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC